LienTeh.net > Ads > TRAMEDX (Trametinib)

TRAMEDX (Trametinib)

Inquire / Price

Model Number：

RL1020230315540
Brand Name：

TRAMEDX
Origin：

Generic drug，Laos
Small Orders：

Small batches also available
Tags：

BRAF V600E Mutation-Positive Solid Tumors Thyroid Cancer Melanoma Lung Cancer

Inquire Now Link

Poster

Details
Description

Packaging Size

30T/bottle
Strength

2mg
Compositon

Trametinib
Treatment

BRAF V600E Mutation-Positive Solid Tumors,Melanoma,Non-Small Cell Lung Cancer,Locally Advanced or Metastatic Thyroid Cancer,
Form

Tablet
Brand

TRAMEDX
Quantity Unit

2mg*30T/bottle
Manufacturer

BIGBEAR Pharma,Laos PDR

Contents hide

1 Melanoma

1.1 BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma

1.2 Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma

2 Non-Small Cell Lung Cancer

3 Thyroid Cancer

4 BRAF V600E Mutation-Positive Solid Tumors

Trametinib is a kinase inhibitor used alone or in combination with dabrafenib to treat patients with cancers with specific BRAF mutations, such as melanoma and non-small cell lung cancer.

Melanoma

Also see Administration

Mutations must be detected by an FDA-approved test

BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma

Indicated, as a single agent or in combination with dabrafenib
2 mg PO qDay
May also be used in combination with dabrafenib 150 mg PO BID
Continue until disease recurrence or unacceptable toxicity

Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma

Indicated, in combination with dabrafenib, for mutation-positive and involvement of lymph node(s), following complete resection
2 mg PO qDay plus dabrafenib 150 mg PO BID
Continue until disease recurrence or unacceptable toxicity for up to 1 year

Non-Small Cell Lung Cancer

Indicated in combination with dabrafenib for unresectable or metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation

2 mg PO qDay plus dabrafenib 150 mg PO BID

Continue treatment until disease progression or unacceptable toxicity

Thyroid Cancer

Indicated, in combination with dabrafenib, for locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation in adults with no satisfactory locoregional treatment options

2 mg PO qDay plus dabrafenib 150 mg PO BID

Continue treatment until disease progression or unacceptable toxicity

BRAF V600E Mutation-Positive Solid Tumors

Indicated in combination with dabrafenib for unresectable or metastatic solid tumors with BRAF V600E mutation in patients who have progressed following prior treatment and have no satisfactory alternative treatment options

2 mg PO qDay plus dabrafenib 150 mg PO BID

Continue treatment until disease progression or unacceptable toxicity